| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2001;32:2748.)
© 2001 American Heart Association, Inc.
Original Contributions |
From Neurovascular Service, Department of Neurology (S.C.J., C.M.); Division of Vascular Surgery, Department of Surgery (L.M.M.); Department of Neurological Surgery (M.T.L.); and Division of Infectious Diseases, Department of Medicine (D.D.), University of California, San Francisco; California Pacific Medical Center Research Institute, San Francisco (W.S.B.); and Childrens Hospital of Oakland Research Institute, Oakland, Calif (D.D.).
Correspondence to S. Claiborne Johnston, MD, PhD, Department of Neurology, Box 0114, University of California, San Francisco, 505 Parnassus Ave, M-798, San Francisco, CA 94143-0114. E-mail clayj{at}itsa.ucsf.edu
| Abstract |
|---|
|
|
|---|
Methods Serum C-reactive protein levels were obtained before endarterectomy for carotid artery stenosis. Plaques were tested for C pneumoniae mRNA, an indicator of viability, and DNA by polymerase chain reaction of DNA and cDNA, respectively.
Results Forty-eight samples were studied, of which 18 (38%; 95% CI, 23 to 50) were infected with viable C pneumoniae as evidenced by isolated chlamydial mRNA. All 18 of these samples, plus 1 additional sample, were positive for chlamydial DNA. Serum C-reactive protein levels were higher in those with viable C pneumoniae compared with those without infection (median, 8 mg/L versus undetectable; P=0.045 by Wilcoxon rank-sum test). In multivariable models, the only independent predictor of the presence of viable C pneumoniae was a detectable C-reactive protein level (odds ratio, 4.2; 95% CI, 1.1 to 17; P=0.04).
Conclusions Viable C pneumoniae are present in a substantial portion of carotid artery atherosclerotic plaques and are associated with increased serum C-reactive protein levels. These findings may explain the link between elevated C-reactive protein levels and the risk of cardiovascular disease and stroke but should be reproduced in a larger cohort.
Key Words: atherosclerosis carotid arteries Chlamydia pneumoniae C-reactive protein inflammation
| Introduction |
|---|
|
|
|---|
Focal inflammation is present in atherosclerotic plaques and has been associated with the progression of vascular stenosis and its complications.69 Chronic infection of arteries has been proposed as a cause of inflammation and a contributor to the initiation and progression of atherosclerosis. Polymerase chain reaction (PCR), immunocytochemical staining, and electron microscopy are among the techniques that have demonstrated evidence of Chlamydia pneumoniae infection in coronary and carotid artery plaques.1016 Detection of viable organisms, a clearer indicator of ongoing infection, has been more difficult. In 4 studies, viable C pneumoniae has been cultured from a small proportion of atherosclerotic plaques.12,14,17,18 In another study, evidence of viable C pneumoniae was found in 10 of 30 patients by isolation of RNA and reverse-transcriptase (RT) PCR.19
Chronic infection of blood vessels with C pneumoniae could lead to elevation of C-reactive protein levels and contribute to the instability or progression of atherosclerotic plaques.2023 Several studies have found an association between C-reactive protein and serological evidence of C pneumoniae infection, whereas others have not.2429 These variable results may be explained by poor correlation between positive chlamydial serologies and evidence of plaque infection.12,16,18,30 One study compared C-reactive protein levels in patients with and without PCR evidence of C pneumoniae in atherosclerotic plaques and failed to find a statistically significant difference.16 Thus, the connection between C pneumoniae plaque infection, systemic inflammation, and symptomatic vascular disease remains uncertain. To determine whether viable C pneumoniae organisms are present in atherosclerotic plaques and whether these organisms are associated with inflammation and the risk of stroke, we evaluated vascular risk factors, signs and symptoms of infection, preoperative serum C-reactive protein levels, and presence of viable C pneumoniae in carotid tissue in a prospective study of patients undergoing elective carotid endarterectomy.
| Subjects and Methods |
|---|
|
|
|---|
Symptomatic carotid arteries were defined as those associated with stroke or transient ischemic attack. An operation on a previously treated artery was defined as a repeated endarterectomy. Antibiotics considered effective in treating C pneumoniae included tetracycline, doxycycline, erythromycin, clarithromycin, azithromycin, and ofloxacin. Symptoms and diagnoses of infection and antibiotic usage were recorded if they occurred during the year before surgery. Cough, sore throat, nasal congestion, and sinus congestion were defined as symptoms of upper respiratory infection. Respiratory infections included diagnoses of common cold, flu, pneumonia, bronchitis, and sinusitis.
C-Reactive Protein Assay
All blood samples were drawn before surgery. C-reactive protein levels were determined with fixed-rate nephelometry (Nichols Institute, Quest Diagnostics), the most sensitive test available at study initiation; the technique is sensitive to levels >4 mg/L.31 Levels below the detection threshold (<4 mg/L) were defined as not detectable.
Carotid Samples
Atherosclerotic tissue was removed by the operating physician using standard surgical techniques. The tissue was sectioned immediately through the center of the widest portion of arterial wall. One section was placed in a sterile Eppendorf tube and another in a tube containing 500 µL RNAzol B (Tel-Test, Inc). Both vials were stored at -80°C until processed. DNA was extracted and purified as previously described.3234 We performed PCR to identify chlamydial infection in carotid atherosclerotic plaques using genus-specific primers to detect any of the 3 chlamydial species (C trachomatis, C pneumoniae, or C psittaci). We used nested PCR in positive-PCR specimens to determine the chlamydial species present.3335 To confirm appropriate size, PCR products were compared with molecular-weight markers by electrophoresis on an agarose gel.
Messenger RNA was extracted from the tissue samples in accordance with the manufacturers protocol (Tel-Test, Inc) and subjected to RT-PCR to generate cDNA for PCR amplification.36 The cDNA was subjected to PCR and agarose gel size verification as described above. In addition, primers specific for HPRT, a housekeeping gene, were used in PCR for each cDNA sample to determine the adequacy of the sample; all samples were amplified by these primers. Quantification of bacterial load was measured in all samples positive for C pneumoniae by use of competitive PCR with known amounts of a polycompetitor cDNA containing C pneumonia. The polycompetitor contains an insert that increases its molecular weight compared with the wild type.37 Briefly, the polycompetitor was used in concentrations of 1, 10, 50, and 100 copies and run with each batch of patient samples for the PCR. A master mix was created that included all the ingredients for PCR except for the patient and polycompetitor samples. The master mix was divided equally among these samples; the respective sample cDNA or polycompetitor sample was added to the respective tube; and all tubes were subjected to the same PCR thermocycling parameters at the same time. Ten microliters of each patient and polycompetitor sample was run on a 1.5% agarose gel stained with ethidium bromide. The quantity of cDNA in the sample was determined by comparison with the results for the 4 concentrations of polycompetitor with the use of a Bio-Rad gel documentation system according to the manufacturers instructions. Samples that contained
1 copy of mRNA in the quantitative assay were considered to have viable organisms.
Statistical Analysis
Dichotomous variables were compared with Pearsons
2 test or Fishers exact test when any cell of a 2x2 table was <5. Exact 95% CIs for prevalent C pneumoniae were calculated by use of exact binomial probabilities. C-reactive protein levels, age, and pack-years of smoking were compared with the Wilcoxon rank-sum test, because these variables were not normally distributed. Multivariable logistic regression analysis was performed, including all variables associated with the presence of viable C pneumoniae (at P<0.20) and removing those no longer contributing (at P>0.10) in a stepwise manner. All statistical analyses were performed with the STATA statistical package (version 6.0).
| Results |
|---|
|
|
|---|
A total of 48 endarterectomy samples were obtained from 46 patients (mean±SD age, 72±8 years), 14 (30%) of whom were female. In 15 patients (31%), the treated carotid artery was associated with symptoms caused by stroke or transient ischemic attack; the remaining patients were asymptomatic. The procedure was a reoperation in 4 patients (8%). Vascular risk factors were common, including smoking (n=37), hypercholesterolemia (n=33), hypertension (n=31), and diabetes mellitus (n=10). Of the 44 patients who provided information on signs and symptoms of infection, 35 (80%) identified a diagnosis or symptoms of infection in the year before endarterectomy, most frequently consistent with respiratory infection (n=32, 73%).
Serum C-reactive protein levels before endarterectomy ranged from undetectable to 86 mg/L, with a median below the detection threshold; 21 patients had detectable levels. Detectable C-reactive protein levels were associated with a history of vomiting, diarrhea, or the taking of antibiotics in the prior year (the Table).
|
PCR revealed evidence of C pneumoniae in 19 carotid plaques (40%). Eighteen of these showed evidence of viable C pneumoniae (38%; 95% CI, 23 to 50) on the basis of the presence of chlamydial RNA. Two patients had bilateral endarterectomies; 1 had evidence of viable C pneumoniae in both plaques, whereas neither plaque from the other patient was infected. Patients with viable C pneumoniae were somewhat more likely to report signs and symptoms of infections in the prior year (the Table).
Serum C-reactive protein levels were greater in patients with viable C pneumoniae than in those without evidence of viable chlamydial organisms (median, 8 mg/L versus not detectable; P=0.045; the Figure). Viable C pneumoniae were twice as common in those with detectable serum C-reactive protein levels than in other patients [52% (11 of 21) versus 26% (7 of 27); P=0.06]. In multivariable models, the only independent predictor of the presence of viable C pneumoniae was a detectable C-reactive protein level (odds ratio, 4.2; 95% CI, 1.1 to 17; P=0.04); the presence of signs or symptoms of infection in the prior year was retained in the model but was not a significant predictor (odds ratio, 6.6; 95% CI, 0.7 to 64; P=0.10). No other demographic characteristics or vascular risk factors were predictors. The presence of viable C pneumoniae was not associated with neurological symptoms at presentation.
|
| Discussion |
|---|
|
|
|---|
40% of plaques removed at endarterectomy had evidence of viable organisms. Infection appeared to be unrelated to vascular risk factors, signs and symptoms suggestive of infection, or presentation with stroke or transient ischemic attack. Similar to results of prior studies,12,15,20 we found that vascular infection with C pneumoniae appears to be asymptomatic. Other groups have demonstrated viable C pneumoniae from cultures of atherosclerotic plaques in the coronary,12,18 femoral,17 and carotid arteries,14,17 albeit in only 4% to 16% of specimens. A single study used RT-PCR in carotid endarterectomy tissue and found evidence of viable C pneumoniae in 10 of 30 patients,19 a detection rate much greater than those seen in studies that used culture. We found a similar rate of infection, which was corroborated by PCR of independently extracted DNA. Furthermore, we showed that plaques with viable infections contained a large number of organisms, suggesting that these infections could be clinically relevant. Characteristics of the referral population we studiedlargely non-Hispanic white and referred for elective treatmentmay have influenced the prevalence of C pneumoniae we found.
This is the first study to demonstrate higher serum C-reactive protein levels in patients with viable carotid C pneumoniae. This association may explain why the C-reactive protein level is a risk factor for stroke and cardiovascular events: Higher levels may indicate chronic arterial wall infection with C pneumoniae, which in turn may contribute to plaque progression.2023 Recent in vitro studies have shown that C pneumoniae infection of human smooth muscle cells results in production of interleukin-6,38 which is the major regulator of C-reactive protein production,39 providing a plausible pathophysiological link.
Our findings could also be explained by an unrecognized factor that increases C-reactive protein levels and increases the risk of C pneumoniae infection. For example, an underlying susceptibility to infection could be associated with both elevated C-reactive protein levels and C pneumoniae infection without a causal link between the 2 factors. We did not identify such a factor in this study, but our sample was small.
Others have studied C-reactive protein in C pneumoniae infection, but they have not attempted to detect viable organisms. One study that compared C-reactive protein levels in those with and without PCR evidence of C pneumoniae DNA16 reported that mean levels were higher (but not significantly so) in those who were PCR positive. Several groups have studied the association between C-reactive protein and positive serologies for C pneumoniae, with conflicting results.2429 Recent studies have shown, however, that serology is a poor marker for the presence of C pneumoniae DNA or RNA.12,16,18,30
If chronic vascular infection with C pneumoniae is responsible for C-reactive protein elevation, treatment should be associated with reduced C-reactive protein levels. Three small trials have tested whether antibiotics directed at C pneumoniae reduce vascular events and inflammatory markers in high-risk patients. All 3 studies demonstrated reductions in C-reactive protein levels in those treated with antibiotics,4042 and 1 study demonstrated a reduction in vascular events.40 The reduction in C-reactive protein after treatment could be due to eradication of C pneumoniae or, alternatively, of other infectious agents treated by these antibiotics.
The association that we found between the presence of viable C pneumoniae and detectable levels of C-reactive protein should be reproduced in a larger group of patients. More sensitive tests for C-reactive protein are now available and could provide additional information, particularly because cohort studies have shown that differences in levels below the detection limit of our assay are associated with the risk of cardiovascular events.3,4 The fact that we detected a difference with a less sensitive, first-generation test suggests that the association between levels of C-reactive protein and the presence of viable C pneumoniae is strong. However, because the positive predictive value of a detectable C-reactive protein level is low with the less sensitive test, it should not be used as a screening test to identify those with viable C pneumoniae.
| Acknowledgments |
|---|
Received July 16, 2001; revision received August 21, 2001; accepted September 5, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. G. Joyee, H. Qiu, S. Wang, Y. Fan, L. Bilenki, and X. Yang Distinct NKT Cell Subsets Are Induced by Different Chlamydia Species Leading to Differential Adaptive Immunity and Host Resistance to the Infections J. Immunol., January 15, 2007; 178(2): 1048 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.E. den Hartog, S.A. Morre, and J.A. Land Chlamydia trachomatis-associated tubal factor subfertility: immunogenetic aspects and serological screening Hum. Reprod. Update, November 1, 2006; 12(6): 719 - 730. [Abstract] [Full Text] [PDF] |
||||
![]() |
T W Weiss, H Kvakan, C Kaun, M Prager, W S Speidl, G Zorn, S Pfaffenberger, I Huk, G Maurer, K Huber, et al. No evidence for a direct role of Helicobacter pylori and Mycoplasma pneumoniae in carotid artery atherosclerosis J. Clin. Pathol., November 1, 2006; 59(11): 1186 - 1190. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Johnston, H. Zhang, L. M. Messina, M. T. Lawton, and D. Dean Chlamydia pneumoniae Burden in Carotid Arteries Is Associated With Upregulation of Plaque Interleukin-6 and Elevated C-Reactive Protein in Serum Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2648 - 2653. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.E. den Hartog, J.A. Land, F.R.M. Stassen, A.G.H. Kessels, and C.A. Bruggeman Serological markers of persistent C. trachomatis infections in women with tubal factor subfertility Hum. Reprod., April 1, 2005; 20(4): 986 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Lindsberg and A. J. Grau Inflammation and Infections as Risk Factors for Ischemic Stroke Stroke, October 1, 2003; 34(10): 2518 - 2532. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yaffe, K. Lindquist, B. W. Penninx, E. M. Simonsick, M. Pahor, S. Kritchevsky, L. Launer, L. Kuller, S. Rubin, and T. Harris Inflammatory markers and cognition in well-functioning African-American and white elders Neurology, July 8, 2003; 61(1): 76 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Khairy, S. Rinfret, J.-C. Tardif, R. Marchand, S. Shapiro, J. Brophy, and J. Dupuis Absence of Association Between Infectious Agents and Endothelial Function in Healthy Young Men Circulation, April 22, 2003; 107(15): 1966 - 1971. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Prager, Z. Turel, W. S. Speidl, G. Zorn, C. Kaun, A. Niessner, G. Heinze, I. Huk, G. Maurer, K. Huber, et al. Chlamydia pneumoniae in Carotid Artery Atherosclerosis: A Comparison of Its Presence in Atherosclerotic Plaque, Healthy Vessels, and Circulating Leukocytes From the Same Individuals Stroke, December 1, 2002; 33(12): 2756 - 2761. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sander, K. Winbeck, J. Klingelhofer, T. Etgen, and B. Conrad Reduced Progression of Early Carotid Atherosclerosis After Antibiotic Treatment and Chlamydia pneumoniae Seropositivity Circulation, November 5, 2002; 106(19): 2428 - 2433. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |